AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its first-in-class positron emission tomography (PET) tracer ACI-19626, at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026).
– Initial data indicates significantly higher tracer uptake in patients with genetically defined FTD
– Good safety and tolerability and suitable PK profile for human brain imaging
– Potentially enables precision medicine across multiple neurodegenerative diseases